Corporate News - News - XZenith Biopharm

News center

Enterprise dynamics

Corporate News

All

Pilosidil tablets receive approval for first-line indication, becoming the first and only comprehensive treatment regimen for advanced HR+/HER2-negative breast cancer in China

Xuanzhu Biopharmaceuticals' self-developed Class 1 innovative drug pirroticlib tablets (brand name: Xuanyuening&...

International Reviews on Antrazole: Overcoming the Limitations of Traditional PPIs and Jointly Initiating a New Era of Stable Acid Suppression Therapy with P-CAB

Acid-related disorders are prevalent gastrointestinal conditions worldwide. Although proton pump inhibitors (PPIs) have ...

XZenith completed the B round of financing of more than 600 million RMB, accelerating the global layout of innovative drug business

Xuanzhu Biopharmaceutical Co., Ltd. completed the round B financing of more than 600 million RMB on December 31,2021. Th...

<1 2 >